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Abstract
A chance observation has led to the development of a new murine model for inflammatory
arthritis. Arthritis is induced, and transferred, by T-cell-dependent antibodies to glucose-6-
phosphate isomerase. This enzyme is expressed in all cells, and is detectable in serum.
There are several similarities to rheumatoid arthritis (RA) in the murine disease. This elegant
model raises several questions as to how and why a systemic response focuses
inflammation so strongly on synovial joints. The model also re-introduces the possibility that
antibodies to widely expressed self-proteins may play a role in the pathogenesis of RA.
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Introduction
The etiology and pathogenesis of rheumatoid arthritis (RA)
remain a mystery, despite the efforts of many investigators
over the past 40 years. RA at one time was labeled a ‘col-
lagen vascular disease’, but the discovery of rheumatoid
factor – an immunoglobulin M antibody that is specific for
the Fc fragment of immunoglobulin G – sparked the idea
that rheumatoid factor itself or other antibodies could rep-
resent the pathogenic effector mechanism. Experiments in
the 1950s through the 1970s failed to substantiate this
concept. The finding that rheumatoid factors were present
in many chronic infections (malaria, subacute bacterial
endocarditis), and the finding by Vaughan that transfer of
large amounts of serum from patients with active RA failed
to induce any disease in the recipients, was taken as evi-
dence that antibodies did not represent major effector
mechanisms in RA [1].
In the 1970s, early studies by Stastny, and later studies by
Gregersen, Winchester, and many others (see [2])
showed that patients with chronic, active, rheumatoid
factor-positive RA had a striking increase in the incidence
of the major histocompatibility complex (MHC) class II
alleles human leukocyte antigen-DRB1*0401, -DRB1*0404,
and -DRB1*0101. It became increasingly clear over the
ensuing years that MHC class II molecules were responsi-
ble for positive and negative selection of CD4+ helper
T cells in the thymus, and for the presentation of self and
foreign peptide antigens to the CD4+ helper T-cell reper-
toire in the periphery. These two factors led many
researchers in this field to entertain the concept that the
pathogenic effector agent in RA was the CD4+ helper
T cell. This concept gained support from early studies that
showed that chronic thoracic duct drainage, with removal
of the predominantly T-cell population in this fluid, resulted
in a partial remission in patients with active RA [3]. Many
other findings – the response to immunosuppressive and
cytotoxic agents, the prominence of CD4+ T cells in the
mixed cellular infiltrate in the rheumatoid synovium, the
increased expression of MHC class II molecules in thisArthritis Research    Vol 2 No 2 McDevitt
tissue, and other results – were taken as circumstantial
evidence in support of the primacy of T cells in the patho-
genesis of the synovitis and bony erosion in active RA.
Further progress in this field has been stymied by the
failure to identify a convincing target autoantigen(s) that is
assumed to be the target of the CD4+ effector T cells. A
number of animal models have been developed to study
the role of several joint proteins as potential target anti-
gens. These include arthritis induced by type II collagen,
proteoglycan, human heat shock protein-60, and other
antigens expressed in chondrocytes and macrophages
under conditions of inflammation, such as human chondro-
cyte glycoprotein 39. Animal models that use these pro-
teins to induce arthritis usually require complete Freund’s
adjuvant, are usually limited to one brief period of arthritis
followed by inactive residual joint damage, and manifest
varying degrees of requirement for CD4+ T cells and spe-
cific antibody to transfer disease into normal syngeneic
recipients [4,5]. Most studies in patients with RA have
reported a very low incidence (less than 25%) of either
specific antibody or proliferative T-cell responses to these
proteins [5,6]. More detailed studies [7], however, have
shown that most patients with seropositive RA have syn-
ovial tissue B cells that actively secrete antibodies to type
II collagen. In the light of more recent findings, these
earlier studies perhaps deserve a second and closer look.
In the absence of a closely parallel spontaneous animal
model [such as the nonobese diabetic (NOD) mouse as a
model for type I (insulin-dependent) diabetes mellitus in
humans], and in the absence of a convincing target
autoantigen, many researchers in this field have clung to
the concept that CD4+ T cells are the prime effector
mechanism that initiates the rheumatoid process, and the
‘true autoantigen’ has yet to be found. The recent demon-
stration that tumor necrosis factor (TNF)-a blockade,
which exacerbates autoimmunity in the NOD mouse and
the NZB×NZW F1 mouse, has a striking therapeutic effect
in RA has been taken as evidence that the final common
pathway in RA is macrophage activation, presumably trig-
gered by cytokines released by activated T-helper-1 type
CD4+ T cells.
The possibility that autoantibody to a systemic self-antigen
could also be a principal effector mechanism for initiation
of the inflammatory process in the joint has been relegated
to a distant second place, for many of the reasons noted
above. Certainly, in my mind, autoantibody as a principal
agent in initiating the synovitis and bony erosions seen in
RA has not been given serious consideration. This prevail-
ing paradigm must now be re-examined in the light of an
elegant series of papers by the group of Benoist and
Mathis, culminating in two recent reports in Arthritis and
Rheumatism [8] and Science [9]. These reports present
convincing evidence that T-cell reactivity and autoantibody
to a ubiquitous self-antigen, glucose-6-phosphate iso-
merase (GPI), are capable of inducing a disease with
many features of RA. Most strikingly, arthritis can be trans-
ferred with serum or with purified antibody to the systemic
autoantigen. The origins of this model are straightforward,
but as with many phenomena in immunology, are some-
what complex in nature, arising as they do out of a
serendipitous observation.
A new arthritis model
The story begins with the production of a line of mice that
are transgenic for a T-cell receptor (TCR) that was origi-
nally isolated from a T-cell clone specific for the bovine
ribonuclease peptide residues 41–61, presented by the
I-Ak MHC class II molecule. In the arcane lingo of immunol-
ogists, this TCR is said to be specific for ribonuclease
41–61 and restricted by the I-Ak molecule, resulting in the
majority of T cells in the periphery expressing this TCR. In
this transgenic mouse, however, the level of expression of
the transgenic TCR in the periphery was low.
In order to introduce a TCR a-chain-null mutation, Benoist
and Mathis crossed their TCR transgenic with a NOD line,
which was available in the laboratory and which carried
this targeted recombinant. Completely unexpectedly, mice
expressing the TCR transgene and the I-Ag7 molecule
developed a severe arthritis, with rapid onset beginning at
about 3 weeks of age. The arthritis observed in these mice
has several similarities to RA, including the following: the
arthritis is chronic, progressive, symmetric, and exhibits a
distal to proximal gradient of severity; it is MHC class II
allele specific; and is characterized by synovitis, pannus
formation, and cartilage and bone destruction, with
increased production of TNF-a and interleukin-6, and
partial dependence on the action of TNF-a. Additional
characteristics that are unlike RA are the great severity,
rapid progression, distal interphalangeal joint involvement,
occasional mild involvement of the spine, and complete
absence of rheumatoid factor activity.
Over the past 5 years, the group of Mathis and Benoist
have executed an experimental tour de force, culminating in
the two studies referred to above [8,9]. By a variety of
crosses, including the introduction of an I-Ag7 b-chain trans-
gene, they have demonstrated an absolute requirement for
the presence of this MHC class II molecule for the develop-
ment of the arthritic phenotype [10]. Additional crosses
involving several types of targeted recombination (knock-
out) mice have also established an absolute requirement for
both T cells (expressing the transgenic TCR) and B cells in
the spontaneous development of the disease [10].
To explore this phenomenon further, the group of Benoist
and Mathis [11] next carried out a series of experiments
utilizing transfer of splenocytes, purified spleen CD4+ T
cells, and purified B cells from arthritic donors into ahttp://arthritis-research.com/content/2/2/085
variety of recipients, with and without the I-Ag7 molecule,
and into a variety of recipients completely lacking their
own T and B cells. These studies showed that an I-Ag7
restricted B-cell function, as well as the transgenic TCR, is
critical for the development of the disease. The use of
mouse lines expressing a restricted immunoglobulin reper-
toire (through the introduction of rearranged VDJ heavy
chain and/or VJ light chain immunoglobulin gene seg-
ments ‘knocked-in’ to the germline) showed that, as the
immunoglobulin repertoire became more and more
restricted, arthritis development was delayed and, in the
double heavy chain and light chain immunoglobulin trans-
genics, was completely eliminated. These results sug-
gested that a specific B-cell product was required for the
development of disease. Further studies (described in [11])
indicated that arthritis development required I-Ag7, and an I-
Ag7 restricted, CD40-dependent, T cell–B cell interaction
that occurred after the initial T cell stimulation. These
results pointed to the possibility that immunoglobulins pro-
duced as a result of this interaction could be important
effector molecules in the development of the arthritis.
Serum transfer studies [11] clearly established the ability
of serum from arthritic, transgenic TCR- and I-Ag7-positive
donors to induce the rapid onset of arthritis in both healthy
and B-cell-deficient or lymphocyte-deficient recipients.
Further experiments quickly established that the
immunoglobulin G fraction of serum was capable of induc-
ing arthritis in both normal and immunodeficient recipients.
Serum-transferred arthritis was transient, resolving in
15–30 days, but persistent active arthritis could be
induced by repeated injections of serum from arthritic
donors. Additional transfers showed that the most severe
arthritis developed in recipients that still expressed the
transgenic TCR, showing that the specific T cells can
increase the severity of the disease, even at late stages.
In the most recent studies [8,9] those investigators used
serum from arthritic mice in immunoblots of tissue extracts
from ankle, spleen, and kidney to show that this serum
identified a 60-kDa protein that appears to be present in
many different tissues. Purification of this 60-kDa protein,
followed by trypsin digestion and amino acid sequencing of
three of the tryptic peptides, revealed that all three peptide
sequences were included in the amino acid sequence of a
ubiquitous enzyme: GPI. The complementary DNA that
encodes GPI was amplified by polymerase chain reaction,
cloned, and placed in an Escherichia coli expression vector
as a glutathione S-transferase (GST) fusion protein. This
permitted the expression of GPI with the GST tag in E coli,
and the construction of GPI–GST affinity columns, along
with GST-only control columns. Using these columns, it
was possible to show that all of the arthritogenic activity in
arthritic donor serum was completely bound to the
GPI–GST column, and that the flow-through immunoglobu-
lins completely lacked the ability to transfer arthritis.
These experiments establish beyond any doubt that anti-
bodies to GPI are the arthritogenic immunoglobulins that
are contained in serum from the transgenic, arthritic mice.
Further studies [9] showed that these antibodies are first
detected in the blood at low concentrations at 3 weeks
after birth – the time of arthritis onset – and increase
steadily until age 8–10 weeks.
The authors then went on to show that the ribonuclease-
specific, I-Ak-restricted, transgenic TCR is also specific for
a peptide (as yet unidentified) from GPI when presented
by I-Ag7. This situation is illustrated in Figure 1. Highly puri-
fied recombinant GPI presented by I-Ag7 antigen-present-
ing cells is capable of stimulating the transgenic T cells to
the same extent as the bovine ribonuclease peptide pre-
sented by I-Ak antigen-presenting cells [9].
Thus, this remarkable series of experiments has estab-
lished that a disease primarily localized to joints can
develop as a result of linked T-cell and B-cell autoreactivity
for a self-antigen that is ubiquitously expressed in the cyto-
plasm of all cells in the body [9]. As the authors pointed
out [9], arthritis does not occur as a result of other types
of autoreactivity of this particular TCR. The same trans-
genic TCR can also recognize an unknown self-peptide
presented by an amino acid sequence variant of I-Ak.
When this variant class II molecule is expressed in the
TCR transgenic mice, however, there are no signs of joint
pathology [8]. This result implies that there are highly spe-
cific properties of the recognition of a GPI peptide by the
transgenic TCR. There may also be important and specific
properties of the antigen GPI. This protein is expressed in
the cytoplasm of all cells, and is also detected in the circu-
lation. It is therefore possible that the rare B cell with an
antibody specific for GPI may capture and present pep-
tides from this molecule to T cells with a high degree of
Figure 1
Peptide X is an as yet unidentified peptide from glucose-6-phosphate
isomerase (GPI). The T cell receptor (TCR) that is specific for
ribonuclease (Rnase) 41–61 restricted to I-Ak manifests striking cross-
reactivity to GPI peptide X presented by I-Ag7.efficiency [9]. The antibody can then form complexes with
the free GPI in the circulation, and this may be involved in
the initiation of the arthritic process.
Much remains to be studied in this model before it is com-
pletely understood, and before the implications of this
model for RA can be formulated. First, the identification of
the specific peptide from GPI that is recognized by the
transgenic TCR in the context of I-Ag7 must be deter-
mined. The affinity and the off-rate of this peptide in its
interaction with I-Ag7 will undoubtedly be studied, as will
the affinity and off-rate of the transgenic TCR for the spe-
cific peptide–I-Ag7 complex. Additional functional charac-
terization of the cytokines produced by T cells that express
this receptor in response to cognate peptide–MHC
ligand, and the susceptibility of this cytokine pattern to
manipulation also need to be analyzed in detail.
Numerous additional questions arise. Will immunization
with GPI in either incomplete or complete Freund’s adju-
vant, with the induction of a diverse GPI-specific TCR
repertoire, lead to the induction of arthritis and arthritic
immunoglobulin G in I-Ag7 mice, or in mice with other
MHC class II I-A alleles? These experiments would indi-
rectly address several key questions concerning the
nature of this autoantigen, and the nature and structure of
the joint and the cells within the joint lining. Is there a
unique property of this enzyme, or of other enzymes in the
glycolytic pathway, that causes GPI and similar enzymes
to localize to the joint? Does the subclass of the
immunoglobulin G antibodies play a role in the develop-
ment of the arthritis? Is this process dependent on expres-
sion of the stimulatory Fc receptors (FcRgI and FcRgIII)?
What is the role of complement in the arthritic process? Is
there deposition of specific antibody, GPI, and compo-
nents of the complement cascade?
Benoist and Mathis point out [8] that there may be similari-
ties between this model and the findings referred to in a
review by Zvaifler in 1973 [12]. It will be important to
determine the localization of GPI, if any, in the normal joint
and to enquire as to whether in the normal process of
phagocytosis within the joint polymorphonuclear leuko-
cytes extrude some of their intracellular enzymes during
the course of phagocytosis within the joint, as suggested
in the latter review [12]. Is the access of either antibody or
immune complexes to the joint space greater than access
to other tissue sites, or to endothelial sites that might also
induce local inflammation? Zvaifler [12] cited a number of
electron microscopic studies of synovial and joint tissues
in RA, showing considerable deposition of immunoglobu-
lin and complement. Are such deposits present in the GPI-
specific arthritis model?
Benoist and Mathis [8] also noted several similarities
between this model and the immune system-independent
arthritis induced in mice by the expression of a human TNF
transgene [13,14]. In this model, there is a high level of
expression of human TNF in the synovial lining macro-
phages and fibroblasts. This finding underlines the impor-
tance of determining normal sites of expression of TNF in
joint-related tissues, including synovial macrophages and
subsynovial fibroblasts. As Benoist and Mathis pointed out
[9], their model has many similarities to RA and is also
dependent on TNF-a, in the sense that the severity of arthri-
tis is much decreased in mice deficient in TNF receptor 1.
Two of the most important similarities between this model
and RA are the demonstration that susceptibility to both
diseases is MHC class II allele specific and the arthritic
process is, to a great degree, dependent upon the action
of TNF-a. The striking new finding in this model is the
prominent role of specific antibody to a systemic, ubiqui-
tously expressed cytoplasmic self-antigen. Production of
this antibody is clearly T-cell-dependent, but once pro-
duced the antibody can transfer arthritis to naïve recipi-
ents (albeit the most severe form of the disease is
dependent on the presence of specific T cells and specific
B cells producing a specific antibody).
Implications for the study of rheumatoid
arthritis
As already noted, much more needs to be learned about
this model before its implications for the further study of
RA can be fully appreciated. New models always engen-
der great enthusiasm on the part of some, and reluctant
skepticism on the part of others. It seems clear that this is
not a true model of RA. The disease is induced by a single
transgenic TCR, whereas the disease in humans is, in all
likelihood, due to the effect of a relatively diverse TCR
repertoire. Although it needs to be ruled out, it is unlikely
that GPI is a target autoantigen in RA. Nonetheless,
several important points can be made.
The results of this model suggest that the search for target
autoantigens in RA should be widened to include many
systemic self proteins with expression that is not limited to,
and may initially be very low in, the joint and joint-related
tissues. Second, the nature and specific characteristics
(eg affinity, subclass, Fc receptor, and complement inter-
actions) may be critical in the ability of a particular auto-
antibody to induce arthritis. There are several animal
models of arthritis (eg type II collagen, proteoglycan) in
which autoantibodies can induce a transient arthritis.
Thus, the finding that autoantibodies to GPI can induce
arthritis is not remarkable for the ability to induce arthritis,
but for the specificity of the antibody to a systemic, widely
expressed cytoplasmic self protein. As the study of this
model progresses over the next several years, and hope-
fully as interest in the cell biology and molecular biology of
normal synovial lining cells and subsynovial macrophages
[12] is rekindled, we can hope for important new insights
Arthritis Research    Vol 2 No 2 McDevittthat can be applied to our attempts to understand the
pathogenic process in RA. There is no lack of candidates
for systemically expressed proteins that might be targets
for an arthritis-inducing autoantibody. These include the
already mentioned human chondrocyte glycoprotein 39
and heat-shock protein-60, as well as the Fc fragment of
immunoglobulins, and the deiminated arginine forms of
filaggrin [15,16]. (Antibodies to the latter protein are
reported in 76% of RA sera.)
Conclusion
Whatever the next 5–10 years bring, Benoist, Mathis and
their colleagues are to be congratulated on an elegant,
precise, and impressive series of experiments. They con-
stitute an outstanding example of one of Pasteur’s favorite
aphorisms: Dans le champs de l’observation, l’hasard ne
favorise que les esprits prepareés (In scientific research,
chance favors the prepared mind).
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